PharmAthene secures $13.1 million in equity financing from Panacea Biotec
Under the strategic financing, Panacea Biotec’s subsidiary has purchased approximately 3.73 million shares of PharmAthene common stock at a negotiated price of $3.50 per share. In addition, Panacea
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.